Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation

A new levodopa‐carbidopa intestinal gel ( LCIG ) system featuring a higher levodopa/carbidopa ( LD / CD ) concentration and viscosity, LCIG ‐ HV , is being developed to reduce the intrajejunal volume of LD / CD that is administered as compared to the current commercial formulation, LCIG ‐ LV . This study characterizes the LCIG ‐ HV formulation and compares it to the LCIG ‐ LV formulation via dissolution testing and a clinical pharmacokinetic...